title: Intralesional therapy for in-transit and satellite metastases in melanoma.
abstract: Intratumoral therapy with bacteria/bacterial products dates to at least the 1890s. Over the decades this has expanded beyond the use of microbes and microbial products to include chemicals, cancer chemotherapeutic agents, cytokines, recombinant organisms, and hybrid molecules. The appeal of this method of delivery is the ability to deliver high concentrations of the therapeutic agent directly to the tumor, often with minimal side effects. This article summarizes the use and efficacy of the various agents used in the past and present in the treatment of in-transit and satellite metastases in melanoma.
authors.affiliation: Department of Medical Oncology, Sidney Kimmel School of Medicine, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA. Electronic address: kendra.feeney@jefferson.edu.
authors.forename: Kendra J
authors.initials: KJ
authors.lastname: Feeney
authors.affiliation: Department of Medical Oncology, Sidney Kimmel School of Medicine, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mastrangelo
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000628:therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents
keywords: Bacille Calmette-Guerin; Granulocyte-macrophage colony-stimulating factor; In-transit disease; Intralesional therapy; Melanoma; Rose bengal; Scarification; Vaccinia